Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations.
about
Lesion of the subiculum reduces the spread of amyloid beta pathology to interconnected brain regions in a mouse model of Alzheimer's diseaseIntraneuronal Aβ accumulation induces hippocampal neuron hyperexcitability through A-type K(+) current inhibition mediated by activation of caspases and GSK-3.Structures of Aβ-Related Peptide−Monoclonal Antibody Complexes ,HSV-1 and Alzheimer's disease: more than a hypothesis.Amyloid-β peptide-specific DARPins as a novel class of potential therapeutics for Alzheimer diseaseDisease modifying therapies for Alzheimer's disease targeting Aβ oligomers: implications for therapeutic mechanismsAntibodies against alpha-synuclein reduce oligomerization in living cellsIntracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 miceSynaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterationsDirected selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils.Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer's disease.The type of Aβ-related neuronal degeneration differs between amyloid precursor protein (APP23) and amyloid β-peptide (APP48) transgenic miceMicroRNA-related cofilin abnormality in Alzheimer's disease.What is the role of amyloid precursor protein dimerization?Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosisSynapses, synaptic activity and intraneuronal abeta in Alzheimer's disease.Dopamine transporter endocytic trafficking in striatal dopaminergic neurons: differential dependence on dynamin and the actin cytoskeleton.Amyloid-ß-directed immunotherapy for Alzheimer's disease.Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse modelIntraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease.Monoacylglycerol lipase inhibitor JZL184 reduces neuroinflammatory response in APdE9 mice and in adult mouse glial cellsPassive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.Herpes Simplex Virus type-1 infection induces synaptic dysfunction in cultured cortical neurons via GSK-3 activation and intraneuronal amyloid-β protein accumulationSynaptic activity and Alzheimer's disease: a critical update.Blocking the interaction between apolipoprotein E and Aβ reduces intraneuronal accumulation of Aβ and inhibits synaptic degenerationBeta-amyloid modulation of synaptic transmission and plasticityAdvances on the understanding of the origins of synaptic pathology in AD.Mutant presenilin 1 increases the expression and activity of BACE1Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathologyAntibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance.Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.Vaccination as a therapeutic approach to Alzheimer's disease.Can Alzheimer disease be prevented by amyloid-beta immunotherapy?Early-Onset Network Hyperexcitability in Presymptomatic Alzheimer's Disease Transgenic Mice Is Suppressed by Passive Immunization with Anti-Human APP/Aβ Antibody and by mGluR5 Blockade.Murine models of Alzheimer's disease and their use in developing immunotherapies.Therapeutic applications of antibodies in non-infectious neurodegenerative diseasesTau as a therapeutic target for Alzheimer's diseaseImmunotherapy for tauopathies.
P2860
Q21092910-F368FBDC-9747-404F-8B24-DF44BDC50365Q27307787-E491ADC4-085E-4B27-A200-88D2E1AC2ECEQ27655072-A937DB85-7DB3-43C6-AE5B-E2C9520AA269Q27692651-9FE50469-D0A6-46BC-AE15-34960D51C192Q28655482-9BB32F42-37A1-4272-A181-A6D412C1D1B4Q28680809-51D55883-FFC1-4B88-A0A6-9C5B05C80556Q28743313-CBF3C3D9-A811-4607-81CF-788994EE1F3CQ30486176-62A3DDCC-46F7-48B2-A2CA-F9B9897E2647Q30491040-67515FA8-17B2-4A94-AC12-81C44239296AQ33307478-FF35A8BD-AEA0-491C-AFAC-4EBB727F47FAQ33327152-9934FC47-9597-4F30-AEAF-959F2CBB9540Q33715954-C047D4E3-6D11-484E-965F-2C5B0A764F61Q33778743-154955BB-CD6E-4DDC-846B-259168C3B9A4Q33977500-4E28F112-13CB-4416-9654-4ACF4AE26E43Q33999870-559E71B2-38B6-4DBB-AED9-04AEE76D423BQ34028039-BF3277B2-FFE7-4140-B489-89DFE8B9DE25Q34383082-36DF9B54-CCC3-492C-83FB-E7206516194CQ34548700-59B56B05-41FD-44F7-9113-13438845FA41Q35104249-B19C042B-53F3-4172-BD92-12C940DC3274Q35246412-2AFC15E1-E726-4F64-802D-E7EBA8984159Q35559526-12367395-76FC-4151-AE91-7D7230599F71Q36005623-421FAF27-882C-4FC4-963B-4A3A40EA15C0Q36187501-D373243F-1179-4906-81DD-29C1BE6957EEQ36245276-EE83C523-91EA-4C85-9D94-B4440701D4CBQ36817618-31EB5548-BDBE-4A77-BE8F-C505BEABD077Q36989218-6A29653D-2C5B-4707-BA13-CE17D536378AQ37108156-3C1EE948-BD13-420F-80EB-F4BF9D135AD6Q37152818-17231F7C-FAE8-4571-B352-94E18A021DE2Q37308949-1DA58A72-B08D-422D-A1BF-01610D971DC8Q37311364-F8A673EE-378C-48BF-9748-AB102DDD938AQ37368709-3803FC5B-65F4-4AE5-8816-9213ED0AF7D1Q37623855-E2E62C1F-7F58-4A7D-A81F-3816983CBA68Q37655247-DBE54DA2-0C35-4D55-B9F9-5A87CCE7FD03Q37681432-AF680CDE-AFAA-4684-8819-C0AA8C8BE203Q37688886-E7D87097-D8FD-4BE0-9F77-EE904AF79A73Q37719047-125B18FE-E9DB-4B2A-B68B-B2B2CC62937CQ37752915-A91B17C4-BF99-438E-B03F-4C49662AE0AFQ37862785-567AA058-7728-43C5-9FD9-DAE4ADDCF8A3Q37890451-2EADEA5D-7264-4596-9579-BC29A0F96D55Q37899064-B689C754-3B3B-45A9-B803-C31969521AF1
P2860
Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Internalized antibodies to the ...... against synaptic alterations.
@en
type
label
Internalized antibodies to the ...... against synaptic alterations.
@en
prefLabel
Internalized antibodies to the ...... against synaptic alterations.
@en
P2093
P2860
P356
P1476
Internalized antibodies to the ...... t against synaptic alterations
@en
P2093
Davide Tampellini
Jordi Magrané
Michael T Lin
Reisuke H Takahashi
P2860
P304
18895-18906
P356
10.1074/JBC.M700373200
P407
P577
2007-04-27T00:00:00Z